According to the NCI website, the BCR-ABL/KIT/AKT/ERK inhibitor HQP1351 is an orally bioavailable inhibitor of a variety of kinases. Check for active clinical trials using this agent.

More Information in English:
Link to National Cancer Institute

Ascentage Pharma Releases Updated Data of its Novel BCR-ABL Inhibitor, HQP1351, in an Oral Presentation Nominated for "Best of ASH"

Link to ASH 2019 Presentation

More info on ClinicalTrials.gov